凯利泰(300326) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥213,839,891.49, a decrease of 34.44% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥14,454,178.67, down 77.48% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,841,627.63, a decline of 77.01% compared to the previous year[5]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.0194, representing a decrease of 78.25% year-on-year[5]. - Total operating revenue for Q3 2023 was ¥736,542,512.98, a decrease of 20.6% compared to ¥928,386,863.29 in Q3 2022[27]. - Net profit for Q3 2023 was ¥142,929,992.00, a decline of 28.0% from ¥198,371,348.69 in Q3 2022[28]. - Total comprehensive income for Q3 2023 was CNY 166,128,200.70, a decrease from CNY 273,318,125.89 in Q3 2022, representing a decline of approximately 39.2%[29]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥3,352,417,951.92, a decrease of 1.75% from the end of the previous year[5]. - The company's total assets decreased to ¥3,352,417,951.92 from ¥3,412,148,611.26, a reduction of 1.7%[25]. - Total liabilities decreased significantly to ¥376,937,840.54 from ¥597,447,117.66, a drop of 37.0%[25]. - The company's total liabilities decreased significantly, with current liabilities due within one year dropping by 86.45% to ¥1,571.71 million[11]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥168,267,223.29, down 31.24% compared to the previous year[5]. - The net cash flow from operating activities for the first nine months of 2023 was 16,826.73 million yuan, a decrease of 7,643.31 million yuan or 31.24% compared to the same period in 2022[18]. - Cash inflow from operating activities totaled CNY 946,274,053.34, compared to CNY 1,093,243,683.99 in the same period last year, reflecting a decline of approximately 13.5%[30]. - Cash outflow from operating activities was CNY 778,006,830.05, down from CNY 848,543,289.05, showing a decrease of about 8.3%[30]. - The company's total cash outflow from operating activities decreased by 7,053.65 million yuan, a reduction of 8.31% compared to the previous year[17]. - Net cash flow from operating activities for the period was CNY 168,267,223.29, down from CNY 244,700,394.94 in the previous year, indicating a decrease of about 31.2%[31]. Investment Income - The company's investment income for the year-to-date was ¥2,722.37 million, an increase of 299.52% compared to the same period last year[13]. - The company reported a significant increase in investment income due to the equity investment in Ligetai and Yixin Medical during the reporting period[17]. - The company reported an investment income of ¥27,223,676.10, a significant recovery from a loss of ¥13,644,946.91 in the previous year[28]. - Cash inflow from investment activities was CNY 569,664,054.57, significantly higher than CNY 142,398,840.97 in the previous year, marking an increase of about 299.5%[31]. Expenses - The company experienced a 33.40% reduction in sales expenses, totaling ¥14,176.46 million for the year-to-date[13]. - The company experienced a decrease in sales expenses due to a decline in overall sales scale influenced by centralized procurement policies[17]. - Research and development expenses for Q3 2023 were ¥39,467,061.79, down from ¥45,539,908.36 in Q3 2022, indicating a decrease of 13.9%[27]. Other Comprehensive Income - The company reported a significant increase in other comprehensive income, which rose by 116.85% to ¥4,305.18 million[11]. - Other comprehensive income after tax for Q3 2023 was ¥23,198,208.70, compared to ¥74,946,777.20 in Q3 2022, reflecting a decrease of 69.0%[28].